Condition: Premature Ejaculation · Sponsor: Plethora Solutions Ltd
This study is being done to test the effect of PSD502 (the study medication) compared to placebo in subjects with premature ejaculation. PSD502 is a topical (applied to skin) anesthetic spray containing a mixture of two drugs called lidocaine and prilocaine that will be applied to the penis. Half of the subjects will receive PSD502 and half will receive placebo.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Achieve Clinical Research | Birmingham, Alabama, United States | — |
| Coastal Clinical Research | Mobile, Alabama, United States | — |
| Skyline Urology | Sherman Oaks, California, United States | — |
| Imagine Research of Palm Beach County | Boynton Beach, Florida, United States | — |
| SunCoast Research | Miami, Florida, United States | — |
| Suncoast Research Associates | Miami Lakes, Florida, United States | — |
| Clinical Research Center of Florida | Pompano Beach, Florida, United States | — |
| Primary Care Research | Atlanta, Georgia, United States | — |
| Georgia Clinical Research, Llc | Lawrenceville, Georgia, United States | — |
| Regional Urology, LLC | Shreveport, Louisiana, United States | — |
| Chesapeake Urology Research Associates | Towson, Maryland, United States | — |
| Boston Clinical Trials | Boston, Massachusetts, United States | — |
+ 9 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03578783